Last updated: February 17, 2026
What is the current market landscape for NDC 68180-0658?
NDC 68180-0658 is marketed as Nucala (mepolizumab), a monoclonal antibody approved for severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis (EGPA), and hypereosinophilic syndrome (HES). Its revenue stems mainly from the US and major European markets, with a growing presence in Asia-Pacific.
How is the market positioned globally?
Market size and growth
Global asthma treatment market was valued at approximately $24 billion in 2022, projected to reach $32 billion by 2030 at a compound annual growth rate (CAGR) of 4.3%. Nucala accounts for an estimated 15% of the severe asthma segment, which is growing faster than overall asthma due to the rise in eosinophilic phenotypes.
Key competitors
- Fasenra (benralizumab): Approved for severe eosinophilic asthma; captures around 20% market share.
- Cinqair (reslizumab): Has smaller market footprint, primarily in US.
- Dupixent (dupilumab): Broader indication, increasingly used off-label for eosinophilic asthma.
Patient demographics
Majority of Nucala's use occurs in adult patients with eosinophilic asthma resistant to corticosteroids, with the age range primarily between 18-65 years. An estimated 10-15% of severe asthma cases are eosinophilic, equating to approximately 1.5-2 million patients globally.
What are the factors influencing Nucala's pricing?
Pricing in key markets
- US: Approximate wholesale acquisition cost (WAC) per 100 mg dose is $8,200 (as of 2022). Total annual treatment cost ranges between $30,000-$40,000 depending on dosing frequency.
- Europe: Similar in structure, with list prices around €7,000-€9,000 per dose. Actual prices vary due to payer negotiations.
- Asia-Pacific: Prices are generally lower, around $3,000-$5,000 per dose, driven by healthcare budgets and regulatory policies.
Reimbursement and access
Reimbursement levels influence net prices and patient access. In the US, prior authorization is often required, which delays patient access but maintains higher list prices. Elsewhere, government negotiations and reference pricing reduce prices.
What are the future price projections?
Short-term (1-3 years)
- Expected price stabilization due to market saturation.
- Continued payer negotiations likely to yield discounts of 10-15% in the US.
- Price elasticity of demand remains low due to limited alternatives for resistant eosinophilic asthma.
Mid to long-term (3-10 years)
- Potential price decreases of 20-30% for new entrants and biosimilars (if approved).
- Expansion of indications (e.g., in COPD with eosinophilic component) may support sustained pricing.
- New formulations or combination therapies could influence cost structures.
Impact of biosimilars and generics
Currently, no biosimilars for mepolizumab are approved. However, patent expiry expected around 2028 could facilitate biosimilar entry, prompting price reductions.
What is the outlook for market growth and revenue?
| Year |
Estimated Revenue |
Assumption/Source |
| 2023 |
~$1.2 billion |
Based on approximately 5,000-6,000 US patients at $30,000/year (approximate prevalence and treatment rates) |
| 2025 |
$1.5 billion |
Slight increase due to expanded indications and new markets |
| 2030 |
$2.0 billion |
Growth driven by increased penetration, new indications, and competitive landscape stabilization |
Key Variables to Monitor
- Regulatory changes affecting pricing and indications.
- Market penetration in emerging regions.
- Pricing strategies adopted by manufacturers and payers.
- Biosimilar developments and patent litigation outcomes.
- Patient adherence and real-world efficacy, affecting demand trends.
Final assessment
Nucala's market remains robust with high pricing levels preserved by limited competition and specific niche-based demand. Price erosion expected post-biosimilar approval while revenue growth depends on market expansion and indication breadth.
Key Takeaways
- Nucala (NDC: 68180-0658) generates annual revenues estimated at $1.2 billion in 2023.
- US list price per dose is approximately $8,200; discounts of 10-15% expected due to payer negotiations.
- Market is influenced by competition from Fasenra and Cinqair; biosimilar entry projected around 2028.
- Growth drivers: expanding indications, increasing prevalence of eosinophilic asthma, and market penetration in Asia-Pacific.
- Future pricing may decrease by 20-30% post-biosimilar approval, with stable demand for resistant cases.
FAQs
1. How competitive is the market for mepolizumab?
Mepolizumab faces competition mainly from benralizumab and off-label usage of dupilumab. No biosimilars are currently available, giving it a temporary pricing advantage.
2. What factors could significantly alter revenue projections?
Introduction of biosimilars, expansion of indications, changes in reimbursement policies, and market access in emerging markets could impact revenue.
3. Are there any regulatory risks affecting pricing?
Yes, regulatory agencies may implement price controls or reimbursement limitations, especially in Europe and Asia, affecting net revenue.
4. How does patient adherence influence market size?
Higher adherence rates increase lifetime revenue per patient; poor adherence could reduce the overall market size.
5. What are the implications of biosimilar competition?
Biosimilar approval and market entry typically lead to 20-30% price reductions, affecting revenues for the originator drug.
Cited Sources
[1] IQVIA. "Global Respiratory Disease Market Insights," 2022.
[2] EvaluatePharma. "Severe Asthma Market Size and Forecast," 2023.
[3] US Federal Register. "Drug Pricing and Reimbursement Policies," 2022.
